Pulmonary Embolism News and Research

RSS

A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung.

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Daiichi Sankyo presents subgroup analysis of Hokusai-VTE study at ASH annual meeting

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study.

11 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

French National Expert Committee on Maternal Mortality formulates twenty recommendations

Twenty recommendations have been formulated by the French National Expert Committee on Maternal Mortality with the aim of raising awareness among health professionals and prospective parents, in consultation with the French National College of Obstetricians and Gynaecologists and the French Society of Anaesthetists/Obstetric Anaesthesia Club.

4 Dec 2013

Researchers take close look at medicine's highest volume activity

Laboratory testing is health care's single highest volume activity, with over 5 billion tests performed each year in the U.S.

18 Nov 2013

ATS and ACCP release five recommendations for tests, procedures in pulmonary medicine

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation's Choosing Wisely® campaign, was produced by a collaborative task force assembled by the American Thoracic Society (ATS) and the American College of Chest Physicians (ACCP).

30 Oct 2013

New pulmonary medicine list includes five recommendations to improve patient care and outcomes

A list released today identified five commonly performed tests and procedures in pulmonary medicine that may not always be necessary. The list, part of the ABIM Foundation’s Choosing Wisely campaign, was produced by a collaborative task force assembled by the American Thoracic Society and the American College of Chest Physicians.

30 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis.

30 Sep 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

Biomarker analysis of Vectibix for mCRC published in New England Journal of Medicine

Amgen today announced the publication of a biomarker analysis of Vectibix (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer.

12 Sep 2013

Asthma exacerbates PE risk

Data from Taiwan show that asthma is associated with a significant increase in the risk for pulmonary embolism, particularly in patients who experience exacerbations.

5 Sep 2013

Hokusai-VTE findings provide fresh insight into patients with pulmonary embolism

In the treatment of venous thromboembolism (VTE), the oral anticoagulant edoxaban resulted in equal efficacy and better safety compared to standard warfarin when either drug was used with initial low molecular weight heparin (LMWH), according to the results of the Hokusai-VTE trial.

5 Sep 2013

"Risk calculator" enables doctors to estimate risk of venous thrombosis

In Austria, around 15,000 people a year develop a venous thrombosis, the occlusion of a vein that can result in a pulmonary embolism. A clot breaks free from a vein and travels via the bloodstream to the lungs, where it blocks vessels.

14 Aug 2013

Immune function restored in spinal injured mice

In a new study, researchers at The Center for Brain and Spinal Cord Repair at The Ohio State University Wexner Medical Center show that is possible to restore immune function in spinal injured mice.

7 Aug 2013

August edition of NPS RADAR includes reviews for new medicines listed on PBS

The 10th anniversary edition of NPS RADAR contains reviews for new medicines listed on the Pharmaceutical Benefits Scheme including rivaroxaban (Xarelto), rotigotine patches (Neupro) and mifepristone (Mifepristone Linepharma) followed by misoprostol (GyMiso).

1 Aug 2013

Inhalable gene therapy may restore function of crucial enzyme to reverse deadly PAH

The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led by investigators at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

31 Jul 2013

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

ACC report helps clinicians optimize appropriate use of noninvasive vascular tests

A new report issued today by the American College of Cardiology (ACC) and developed in collaboration with 10 other leading professional societies provides detailed criteria to help clinicians optimize the appropriate use of certain noninvasive vascular tests when caring for patients with known or suspected disorders of the venous (veins) system.

20 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013